SLC16A1 and colorectal cancer: The overexpression of MCT1 sustains a lactate cycle in colorectal cancer cells that are resistant to KRAS mutations and targeting the MCT1 transporter presents a novel approach to surmount resistance to cetuximab in these cells [119].